Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thank you,
I am in the process of doing that. My account started out as a Bank of America with Merrill as a joint account, but BofA recently switched the account over to Edge Merrill. I wanted to pick up CBIS more but was refused.
Merrill Lynch charges 8.95 per trade.
I use Merrill Lynch.
My broker will not let me buy anymore CBIS shares, but they said that I can still sell CBIS shares in my account.
And I was hoping to buy some more before the div.
:(
I think he meant "pouted". LOL
NEWS ALERT !!!!
It's funny that some think that PR's costs lots of money. There is a new PR today. This one is free, like the last one, just because it mentions CBIS by name. I guess they didn't want to post it on Ihub because there are too many whiners about PRs.
1. CBIS a scam ... come on get real.
2. Where do you think they will sell the vapor e-cigs ??
3. Social acceptance of MJ is key to sales.
4. Dr. Bob is the leading expert in this exciting field.
Rockbrook was the lead in putting together the ad ---- many on this board thought that the Cal vote was important.
WTF
Wrong!
Cannabis Science Airs First Paid TV Ad in California
Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB) has received five thousand dollars from a third party (VNC Associates LLC) for one (1) day (which has expired) of advertising for CANNABIS SCIENCE INC (OTC BB: CBIS.OB)
Promotions
isn't inside information just dandy ??
Level II shows a retrenchment of resistance at .05 range.
Selling pressure continues. News of div would sure be nice!!
The yearly, semiannual, quarterly, weekly, AND daily charts are all negative.
Despite CEO and PR statements, long term investing has been costly, because now we have opportunities for the short term investing in flipping.
MMs are doing a good job keeping the spread close....not many spikes, which if there are, the $$$ volume is low.
What would be fun is to see the selling pressure vanish and buying pressure walk this baby back up to .42 cent range on just the strength of this venture.
At least these new products will be sold in dispensaries and there is already a huge market for dispensaries. CBIS needs a dispensary in Cal. so that the products can enter these markets there as well.
It is looking that Oregon will add dispensaries come November as well.
Lots of shorting on Friday
20100910|SFIO|1200160|1747990
With news, this could climb fast.
Here's the same article --- different writer:
Made the bid at .0041 this morning and picked up a few more shares in the afternoon. MM setting on .0040, so I upped it .0001.
:)
GLTA
Chart shows accumulation in the past couple of weeks. Could fly on really good news !!!
Found the entry point last week at .004.
SFIO looks promising. Hoping for US sales soon.
Richard Cowan Interview:
September 1, 2010
"It Wouldn't Matter if It Was Widgets."
(Except, of course, that no one has ever been arrested for smoking a widget.) An interview with Richard Cowan, CFO, Cannabis Science Inc.
Scott Leibs and Leah Tedesco - CFO Magazine
While there may be no such thing as a typical CFO, it's a safe bet that Richard Cowan is less typical than most. Among the more interesting data points on his résumé is his three-year stint (1992–1995) as national director of NORML (the National Organization for the Reform of Marijuana Laws). Today, Cowan holds the distinction of serving as the finance chief at the country's only publicly traded medical-marijuana company, Cannabis Science Inc. (CBIS, traded on the OBB).
A 1962 graduate of Yale, Cowan was anything but a campus radical: he studied economics and served as president of the Yale Young Republicans. He went on to pursue a number of business ventures even as he wrote widely about U.S. drug policy, including a cover story for National Review titled "How the Narcs Created Crack," which has been praised as a pioneering look at the economics of contraband.
Medical marijuana is very much in the news, in part because the Veterans Administration recently eased its opposition to it, at least a little. Business issues aside for the moment, why does this issue appeal to you?
In the early 1990s we [at NORML] held a national medical-marijuana day, using a grant we'd gotten to bring in patients from around the country. They had all kinds of astonishing stories to tell. One guy marched with a long string of pill bottles that had held all the conventional medications he'd been given for headaches and so on after he had been hit by a drunk driver. He'd been able to stop using all of them by using cannabis. Stories like that have an emotional impact on me.
How does a publicly traded company operate in such a legally and politically sensitive environment?
We're following several different paths. First, for the foreseeable future we have to assume that no medical-marijuana product is going to be sold outside of the dispensary system, so we will work with dispensaries to provide standardized products compliant with state laws. We are also working on products for Food and Drug Administration approval, which is what would be needed to sell over-the-counter or by prescription. We have entered into a joint agreement with a company that makes smokeless electronic cigarettes, which have great potential to deliver a precise dose to patients, and we are looking at [nonsmokable] products such as extracts, tinctures, and lozenges. We want to bring the highest scientific standards to what is, right now, sort of an herbal medicine that operates, by necessity, in a gray area.
How did you go from activist to CFO of the country's only publicly traded pharmaceutical cannabis company?
I had known someone for a long time who was a libertarian and a medical-marijuana activist, and he had been told by people that he could get funding for a medical-marijuana company. He wanted to know if I could help him because he had no background in corporate finance, and I said sure. So he started a company and brought in [as CEO] Dr. Robert Melamede, who had retired as the head of the biology department at the University of Colorado, Colorado Springs. The point of going public was to get financing, since at that particular point in time [2008] if you mentioned financing to people they ran screaming from the room. So we decided to go public — unfortunately, just as Lehman Brothers went under. So that threw things off course a little bit.
And there was also some acrimony between the parties involved?
As we were getting started as a public company I received an e-mail threatening to file charges against me [for various alleged improprieties]. Essentially, one person claimed that I was in cahoots with Dr. Melamede to steal from the company. There was nothing to steal! It was not a pleasant situation, but our response became very simple. We voted to oust this person from the three-man board, so we now have a two-man board, Dr. Melamede and me. [As part of this matter Cannabis Science also reached a settlement with K&D Equity Investments that cleared the way for it to issue 3.6 million shares in November 2009; there are now 66 million common shares outstanding.]
What are your respective roles?
Bob [Melamede] is really the key to the company. In some ways he is a typical academic, but he's also an old hippie who doesn't like a lot of the formal corporate stuff. He understands the necessity of it, but he'd much rather wear a T-shirt. My work role, by contrast, is stuck somewhere around 1960. We've gotten the company completely straightened out and now we are getting down to much more conventional priorities. We may be focused on cannabis, but in some sense it wouldn't make any difference if it was widgets — if you're going to develop a new widget you have to look for risk capital and figure out how long it will take to get product development done and how to protect your intellectual property and how else to raise money, and so on.
Where are you channeling your research efforts?
There's a huge amount that we still don't know about how cannabis works — of course, we still don't entirely know how aspirin works, either. When you consider that the plant may have, say, a hundred different cannabinoids, each with maybe a hundred variations, talk about an unbreakable code! Even if there are only a few dozen variations that are worth pursuing, that's still a lot. Which ones will work best for [post-traumatic stress disorder], say, versus other medical conditions? That's the challenge ahead of us as we try to identify the best candidate or candidates for FDA applications.
The revenue at the moment is on the dispensary side, but ultimately will it be the research that provides the real payoff?
There's a company in Britain called G.W. Pharmaceuticals that we look to as a model. They have a product called Sativex that is a whole-cannabis extract, in some sense a sophisticated version of the kind of cannabis tinctures that were on the market back in the late 1930s and 1940s in the United States. It's approved for prescription in Canada and the UK and is about to be approved in Spain. They've taken in close to $100 million in prepaid licensing fees from major pharmaceutical companies. That's a fairly conventional approach in terms of how a new biotech company develops a drug and then either licenses it to a major pharmaceutical company or sells out to the major. As a publicly owned company, we obviously can't say that we would never sell out, because that depends on the bid price, shareholder interest, and so on. So that may or may not happen, but we would be open to a marketing or licensing agreement with a major once we have products in the FDA process.
Who owns your stock?
It's hard to know. There are a few million shares outstanding, and it seems that a fairly wide ownership has developed over the past few months because interest in it has picked up. But the use of street names and other factors make it hard to know who owns what unless you look closely, and frankly I haven't done that.
Do you foresee a day when marijuana will be sold over the counter?
In our public comments we have made it very clear that both Dr. Melamede and I are strongly in favor of the full legalization of marijuana, and we think that most medical-marijuana products should be sold over the counter, which would be the case, obviously, under full legalization. I am still active in the reform movement, but I don't have as much time for activism as I did when that was all I was doing. That said, I often joke that my title should be CPO, for Chief Politics Officer.
First, you said for a fact that you would not post until .0001 and then you posted again on this board. That was a lie.
Secondly, you said:
Bladelawless wrote:
I upped my bid to .0045 today, while it reached the mark a few times, looks like others or mm is supporting that price, for now.
Maybe Monday Lady Lucky will shine me on some shares.
Thanks for the info !!
I put a bid in at .004 today and it did not fill. But then you did not post your concerns about this stock today.
You think I should wait until .001 ??
When do you think this stock will bottom out?
Help me out bud.
I'm looking to buy in here.....waiting for the PPS to go a little lower.
KEEP POSTING BLADE.... I love it when you post.
It should be going down more, eh ???
Is it just me, or are the quality of posts going down hill lately.
Arm chair managers !!! LOL
We need some creeper weed strain to silence the peanut gallery.
20100824|SFIO|1323360|5719500
I think the Q-10 was an improvement, but maybe not the improvement I was hoping for. I was hoping for big strides in reducing debt.
Realizing this is a development corporation, we can expect debt.
I guess the positive side is that the debt did not grow.
Maybe we can expect a slight pop tomorrow. I just wish the selling pressure would vanish.
Actually, I've been tempted to add to my position with such a low price, on the chance that they sold tons of water.
Defunct, Default, and now DEFILED.
lol
Well, not exactly. You stated:
Here's the information of the joint venture filing done on June 11th. NSOS
GLTA
CBIS was pumped by NebulaStocks last Friday for an expected $8000.
What a waste of investor's money. That money could have been better spent in supporting SP rather than decreasing SP.
Ugh!!!
Nebula Stock claims on its landing page implying a 2300% return because of their pumping and that's a lie, because NebulaStock did not pump CBIS last year.
It would be wise to do more digging or dd. The niche these companies are trying to corner are restricted and they have to make their own trail blazing.
Because Vapor Rush contains THC it can only be marketed as containing "THC", "cannabinoids", or "strains" because the FDA prohibits any patented substance or device as being sold as "treating a disease" or "used to treat" a disease without FDA approval. That's where CBIS will dominate the market in the future, as treating pains, medical conditions, and diseases.
CBIS is able to sell cannabis cigarettes under the same state medical marijuana laws, just as Vapor Rush currently does.
The joint venture with Smokefree Innotech was formed on 6-11-2010.
However, there is already an THC-cigarette on the closed market for med patients. It called Vapor Rush
Dade wrote:
So, you were asking because you did not read the notice sent out by CBIS ??
We could see PPS rise in anticipation of a positive quarterly report.
Of course, trading could be slow today while investors take in the news.